| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Valeant Pharms. Int’l Inc. v. Mylan Pharms., Inc., 16-0035 (D.N.J.) | Jan. 4, 2016 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
|
| Otsuka Pharm. Co., Ltd. v. Indoco Remedies Ltd., 16-0086 (D.N.J.) | Jan. 7, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Jazz Pharms., Inc. v. Wockhardt Bio AG, 16-0099 (D.N.J.) | Jan. 7, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Alcon Pharms. Ltd. v. Watson Labs., Inc., 16-0101 (D.N.J.) | Jan. 7, 2016 | Hon. Peter G. Sheridan | Ciprodex® (ciprofloxacin / dexamethasone otic suspension) |
6,284,804
6,359,016
|
| Helsinn Healthcare S.A. v. Sagent Pharms., Inc., 16-0173 (D.N.J.) | Jan. 11, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Prostrakan, Inc. v. Actavis Labs. UT, Inc., 16-0044 (E.D. Tex.) | Jan. 13, 2016 | Hon. Robert W. Schroeder, III | Sancuso® (granisetron extended-release transdermal film) | 7,608,282 |
| Prostrakan, Inc. v. Actavis Labs. UT, Inc., 16-0015 (D. Del.) | Jan. 15, 2016 | Hon. Leonard P. Stark | Sancuso® (granisetron extended-release transdermal film) | 7,608,282 |
| Hospira, Inc. v. Fresenius Kabi USA, LLC, 16-0651 (N.D. Ill.) | Jan. 15, 2016 | Hon. Rebecca R. Pallmeyer | Precedex® (dexmedetomidine hydrochloride injection) |
8,242,158
8,338,470
8,455,527
8,648,106
|
| Rosellini Scientific, LLC v. Grunenthal Gmbh, IPR2016-00471 (PTAB) | Jan. 15, 2016 | N/A |
Nucynta® (tapentadol hydrochloride tablets)
Nucynta® ER (tapentadol hydrochloride extended-release tablets)
Nucynta® (tapentadol hydrochloride solution)
|
7,994,364 |
| Purdue Pharma L.P. v. Abhai, LLC, 16-0025 (D. Del.) | Jan. 19, 2016 | Hon. Sue L. Robinson | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,114,383
8,309,060
8,337,888
8,808,741
8,894,987
8,894,988
9,060,976
9,073,933
|
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 16-0026 (D. Del.) | Jan. 20, 2016 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,198,863
9,205,056
|
| Cubist Pharms. LLC v. Dr. Reddy’s Labs., Ltd., 16-0030 (D. Del.) | Jan. 21, 2016 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Purdue Pharma L.P. v. Abhai, LLC, 16-0058 (M.D. Fla.) | Jan. 21, 2016 | Hon. Timothy J. Corrigan | OxyContin® (oxycodone hydrochloride extended-release tablets) |
7,674,799
7,674,800
7,683,072
8,114,383
8,309,060
8,337,888
8,808,741
8,894,987
8,894,988
9,060,976
9,073,933
|
| Cubist Pharms. LLC v. Dr. Reddy’s Labs., Ltd., 16-0372 (D.N.J.) | Jan. 21, 2016 | Hon. Freda L. Wolfson | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Millennium Pharms., Inc. v. Wockhardt Bio AG, 16-0034 (D. Del.) | Jan. 22, 2016 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-0405 (D.N.J.) | Jan. 22, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) |
8,017,615
8,580,796
8,642,760
8,518,421
|
| Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-0424 (D.N.J.) | Jan. 25, 2015 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Horizon Pharma, Inc. v. Actavis Labs. FL, Inc., 16-0426 (D.N.J.) | Jan. 25, 2016 | Hon. Mary L. Cooper | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
9,161,920
9,198,888
|
| Novartis Pharms. Corp. v. Wockhardt Bio AG, 16-0040 (D. Del.) | Jan. 26, 2016 | Hon. Leonard P. Stark | Gleevec® (imatinib mesylate tablets) |
6,894,051
RE43,932
|
| Jazz Pharms., Inc. v. Roxane Labs., Inc., 16-0469 (D.N.J.) | Jan. 27, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00510 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 6,858,650 |
| Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00512 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 7,384,980 |
| Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00514 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 7,855,230 |
| Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00516 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 8,338,478 |
| Mylan Pharms. Inc. v. UCB Pharma Gmbh, IPR2016-00517 (PTAB) | Jan. 28, 2016 | N/A | Toviaz® (fesoterodine fumarate extended-release tablets) | 7,985,772 |
| Otsuka Pharm. Co., Ltd. v. Stason Industrial Corp., 16-0555 (D.N.J.) | Feb. 1, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,089,567 |
| Otsuka Pharm. Co., Ltd. v. Stason Industrial Corp., 16-0557 (D.N.J.) | Feb. 1, 2016 | Hon. Jerome B. Simandle | Abilify® (aripiprazole tablets) | 9,125,939 |
| Orexo AB v. Actavis Elizabeth LLC, 16-0062 (D. Del.) | Feb. 2, 2016 | Hon. Sue L. Robinson | Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) |
8,454,996
8,940,330
|
| The Medicines Co. v. Eagles Pharms., Inc., 16-569 (D.N.J.) | Feb. 2, 2016 | Hon. Stanley R. Chesler | Angiomax® (bivalirudin for injection) |
7,713,928
7,803,762
|
| Argentum Pharms. LLC v. Alcon Research, Ltd., IPR2016-00544 (PTAB) | Feb. 2, 2016 | N/A | Pazio® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
| Amneal Pharms. LLC v. Jazz Pharms., Inc., IPR2016-00546 (PTAB) | Feb. 2, 2016 | N/A | Xyrem® (sodium oxybate oral solution) | 8,772,306 |
| Lupin Ltd. v. Vertex Pharms., Inc., IPR2016-00558 (PTAB) | Feb. 3, 2016 | N/A | Lexiva® (fosamprenavir calcium) | 6,436,989 |
| Bayer Intellectual Property Gmbh v. Invagen Pharms., Inc., 16-0064 (D. Del.) | Feb. 4, 2016 | Hon. Sue L. Robinson | Xarelto® (rivaroxaban tablets) |
7,157,456
7,585,860
7,592,339
|
| Eli Lilly and Co. v. Dr. Reddy’s Labs., Ltd., 16-0308 (S.D. Ind.) | Feb. 5, 2016 | Hon. Jane Magnus-Stinson | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 16-0645 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
| Horizon Pharma Ireland Ltd. v. Amneal Pharms. LLC, 16-0646 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
| Horizon Pharma Ireland Ltd. v. Teligent, Inc., 16-0647 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
| Horizon Pharma Ireland Ltd. v. Lupin Ltd., 16-0732 (D.N.J.) | Feb. 5, 2016 | Hon. Noel L. Hillman | Pennsaid® (diclofenac sodium topical solution) | 9,220,784 |
| Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., PGR2016-00007 (PTAB) | Feb. 5, 2016 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
| Dr. Reddy’s Labs., Ltd. v. Helsinn Healthcare S.A., PGR2016-00008 (PTAB) | Feb. 5, 2016 | N/A | Aloxi® (palonosetron hydrochloride for injection) | 9,173,942 |
| Helsinn Healthcare S.A. v. Sagent Pharms., Inc., 16-0681 (D.N.J.) | Feb. 8, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
7,947,725
7,960,424
8,598,219
8,729,094
|
| Cubist Pharms. LLC v. Crane Pharms. LLC, 16-0072 (D. Del.) | Feb. 10, 2016 | Hon. Gregory M. Sleet | Cubicin® (daptomycin for injection) |
6,468,967
6,852,689
8,058,238
8,129,342
|
| Bristol-Myers Squibb Co. v. Cipla USA, Inc., 16-0074 (D. Del.) | Feb. 11, 2016 | Hon. Leonard P. Stark | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Pfizer Inc. v. Accord Healthcare, Inc., 16-0079 (D. Del.) | Feb. 11, 2016 | Hon. Sue L. Robinson | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
| Pfizer Inc. v. Accord Healthcare, Inc., 16-0113 (M.D.N.C.) | Feb. 12, 2016 | Hon. Thomas D. Schroeder | Tygacil® (tigecycline injectable IV infusion) |
7,879,828
8,372,995
8,975,242
|
| Purdue Pharma L.P. v. Epic Pharma, LLC, 16-0087 (D. Del.) | Feb. 16, 2016 | Hon. Sue L. Robinson | OxyContin® (oxycodone hydrochloride extended-release tablets) | 9,073,933 |
| AstraZeneca Pharms. LP v. Innopharma, Inc., 16-0894 (D.N.J.) | Feb. 16, 2016 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Mylan Pharms. Inc. v. Yeda Research * Development Co., Ltd., PGR2016-00010 (PTAB) | Feb. 16, 2016 | N/A | Copaxone® (glatiramer acetate injection) | 9,155,776 |
| Boehringer Ingelheim Pharms. Inc. v. Prinston Pharm. Inc., 16-0851 (D.N.J.) | Feb. 17, 2016 | Hon. Peter G. Sheridan | Jentadueto® (linagliptin / metformin hydrochloride tablets) |
8,673,927
8,846,695
|
| Boehringer Ingelheim Pharms. Inc. v. Accord Healthcare, Inc., 16-0852 (D.N.J.) | Feb. 17, 2016 | Hon. Peter G. Sheridan | Jentadueto® (linagliptin / metformin hydrochloride tablets) | 9,173,859 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00078 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 6,455,518 |
| Par Pharm., Inc. v. Novartis AG, IPR2016-00084 (PTAB) | Oct. 26, 2015 | N/A | Zortress® (everolimus tablets) | 5,665,772 |
| Complex Innovations, LLC v. Amgen Inc., IPR2016-00085 (PTAB) | Oct. 26, 2015 | N/A | Sensipar® (cinacalcet hydrochloride tablets) | 7,829,595 |
| Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00627 (PTAB) | Feb. 17, 2016 | N/A | Jevtana® Kit (cabazitaxel solution for infusion) | 5,847,170 |
| Valeant Pharms. Int’l, Inc. v. Actavis LLC, 16-0889 (D.N.J.) | Feb. 18, 2016 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide injection) |
8,247,425
8,420,663
8,552,025
8,822,490
9,180,125
|
| Merck Sharp & Dohme Corp. v. Par Sterile Products, LLC, 16-0948 (D.N.J.) | Feb. 19, 2016 | Hon. Peter G. Sheridan | Noxafil® (posaconazole solution for infusion) | 9,023,790 |
| Sandoz Inc. v. Daiichi Sankyo, Inc., 16-0994 (D.N.J.) | Feb. 22, 2016 | Hon. Renee Marie Bumb | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
| Biomarin Pharm. Inc. v. Par Pharm., Inc., 16-1015 (D.N.J.) | Feb. 22, 2016 | Hon. Michael A. Shipp | Kuvan® (sapropterin dihydrochloride packets) |
7,566,714
7,612,073
8,067,416
RE43,797
|
| Frontier Therapeutics, LLC v. medac Gesellschaft für klinische Spezialpräparate mbH, IPR2016-00649 (PTAB) | Feb. 22, 2016 | N/A | Rasuvo® (methotrexate solution) | 8,664,231 |
| Sandoz Inc. v. Daiichi Sankyo, Inc., 16-0081 (E.D. Va.) | Feb. 22, 2016 | Hon. Arenda L. Wright Allen | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
| Janssen Products, L.P. v. Lupin Ltd., 16-1032 (D.N.J.) | Feb. 23, 2016 | Hon. William H. Walls | Prezista® (darunavir tablets) |
8,518,987
7,126,015
|
| Mylan Pharms., Inc. v. Senju Pharm. Co., Ltd., IPR2016-00626 (PTAB) | Feb. 25, 2016 | N/A | Bepreve® (bepotastine besilate ophthalmic solution) | 8,784,789 |
| Eli Lilly and Co. v. Biocon Ltd., 16-0469 (S.D. Ind.) | Feb. 26, 2016 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed disodium injection) | 7,772,209 |
| Senju Pharm. Co., Ltd. v. Lupin Ltd., 16-1097 (D.N.J.) | Feb. 26, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 9,144,609 |
| Dow Pharm. Sciences, Inc. v. Actavis Labs. UT, Inc., 16-1105 (D.N.J.) | Feb. 26, 2016 | Hon. Stanley R. Chesler | Onexton® (benzoyl peroxide / clindamycin phosphate topical gel) | 8,288,434 |
| Roxane Labs., Inc. v. Vanda Pharms., Inc., 16-0179 (S.D. Ohio) | Feb. 26, 2016 | Hon. Algenon L. Marbley | Fanapt® (iloperidone tablets) |
8,652,776
8,999,638
9,072,742
9,074,254
9,074,255
9,074,256
9,157,121
|
| Roxane Labs., Inc. v. Vanda Pharms. Inc., IPR2016-00690 (PTAB) | Feb. 26, 2016 | N/A | Fanapt® (iloperidone tablets) | 9,138,432 |
| Delcor Asset Corp. v. Taro Pharm. Industries, Ltd., 16-0117 (D. Del.) | Mar. 1, 2016 | Hon. Gregory M. Sleet | Olux-E® (clobetasol propionate topical aerosol foam) |
6,730,288
7,029,659
|
| Duchesnay Inc. v. Apotex Inc., 16-0123 | Mar. 2, 2016 | Hon. Sue L. Robinson | Diclegis® (doxylamine succinate / pyridoxine hydrochloride delayed-release tablets) | 6,340,695 |
| Shire Development LLC v. Lupin Ltd., 16-0612 (D. Md.) | Mar. 2, 2016 | Hon. James K. Bredar | Fosrenol® (lanthanum carbonate oral powder) |
5,968,976
7,465,465
8,980,327
9,023,397
|
| Alcon Research, Ltd. v. Watson Labs., Inc., 16-0129 (D. Del.) | Mar. 4, 2016 | Hon. Sue L. Robinson | Ilevro® (nepafenac ophthalmic suspension) |
7,947,295
8,921,337
|
| Pernix Ireland Pain Ltd. v. Actavis Labs. FL, Inc., 16-0138 (D. Del.) | Mar. 4, 2016 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) | 9,265,760 |
| Pernix Ireland Pain Ltd. v. Alvogen Malta Operations Ltd., 16-0139 (D. Del.) | Mar. 4, 2016 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) | 9,265,760 |
| Takeda Gmbh v. Hetero USA Inc., 16-1280 (D.N.J.) | Mar. 4, 2016 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 5,712,298 |
| Torrent Pharms. Ltd. v. Daiichi Sankyo, Inc., 16-2988 (N. D. Ill.) | Mar. 9, 2016 | Hon. Rebecca R. Pallmeyer | Benicar® (olmesartan medoxomil tablets) | 6,878,703 |
| Cosmo Technologies Ltd. v. Mylan Pharms. Inc., 16-0152 (D. Del.) | Mar. 10, 2016 | Hon. Leonard P. Stark | Uceris® (budesonide tablets) |
7,410,651
8,293,273
8,784,888
RE43,799
|
| Senju Pharm. Co., Ltd. v. Innopharma Licensing, Inc., 16-1361 (D.N.J.) | Mar. 10, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 9,144,609 |
| Ranbaxy Inc. v. Jazz Pharms., Inc., IPR2016-00738 (PTAB) | Mar. 10, 2016 | N/A | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Purdue Pharma L.P. v. Actavis Labs. FL, Inc., 16-0156 (D. Del.) | Mar. 11, 2016 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,198,863
9,205,056
|
| Cosmo Technologies Ltd. v. Mylan Pharms. Inc., 16-0040 (N.D.W.V.) | Mar. 15, 2016 | Hon. Irene M. Keeley | Uceris® (budesonide tablets) |
7,410,651
8,293,273
8,784,888
RE43,799
|
| Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712 (PTAB) | Mar. 15, 2016 | N/A | Jevtana® Kit (cabazitaxel solution for infusion) | 8,927,592 |
| Eli Lilly and Co. v. Teva Pharms. USA, Inc., 16-0596 (S.D. Ind.) | Mar. 16, 2016 | Hon. Tanya Walton Pratt | Forteo® (teriparatide injection) |
6,770,623
7,144,861
7,550,434
6,977,077
7,163,684
7,351,414
|
| Eli Lilly and Co. v. Teva Pharms. USA, Inc., 16-0167 (D. Del.) | Mar. 17, 2016 | Hon. Sue L. Robinson | Forteo® (teriparatide injection) |
6,770,623
7,144,861
7,550,434
6,977,077
7,163,684
7,351,414
|
| Fresenius Kabi USA, LLC v. Dr. Reddy’s Labs., Inc., 16-0169 (D. Del.) | Mar. 17, 2016 | Hon. Gregory M. Sleet | Levothyroxine Sodium |
9,006,289
9,168,238
9,168,239
|
| Jazz Pharms., Inc. v. Watson Labs., Inc., 16-1505 (D.N.J.) | Mar. 17, 2016 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,050,302 |
| Amag Pharms., Inc. v. Sandoz Inc., 16-1508 (D.N.J.) | Mar. 17, 2016 | Hon. Peter G. Sheridan | Feraheme® (ferumoxytol for injection) |
6,599,498
7,553,479
7,871,597
8,501,158
8,591,864
8,926,947
|
| BioDelivery Sciences Int’l, Inc. v. Actavis Labs. UT, Inc., 16-0175 (D. Del.) | Mar. 18, 2016 | Hon. Gregory M. Sleet | Bunavail® (buprenorphine / naloxone buccal film) |
7,579,019
8,147,866
8,703,177
|
| Senju Pharm. Co., Ltd. v. Watson Labs., Inc., 16-1522 (D.N.J.) | Mar. 18, 2016 | Hon. Jerome B. Simandle | Prolensa® (bromfenac ophthalmic solution) | 9,144,609 |
| Fresenius Kabi USA, LLC v. Dr. Reddy’s Labs., Inc., 16-1542 (D.N.J.) | Mar. 18, 2016 | Hon. Kevin McNulty | Levothyroxine Sodium |
9,006,289
9,168,238
9,168,239
|
| Indivior Inc. Teva Pharms. USA, Inc., 16-0178 (D. Del.) | Mar. 21, 2016 | Hon. Richard G. Andrews | Suboxone® (buprenorphine hydrochloride / naloxone hydrochloride sublingual film) |
8,475,832
8,017,150
8,603,514
8,900,497
8,906,277
|
| Medicis Pharm. Corp. v. Zydus Pharms. (USA) Inc., 16-1565 (D.N.J.) | Mar. 21, 2016 | Hon. Renee Marie Bumb | Vanos® (fluocinonide topical cream) |
6,765,001
7,220,424
7,794,738
8,232,264
|
| Salix Pharms., Ltd. v. Actavis Labs. FL, Inc., 16-0188 (D. Del.) | Mar. 23, 2016 | Hon. Gregory M. Sleet | Xifaxan® (rifaximin tablets) |
6,861,053
7,045,620
7,452,857
7,605,240
7,612,199
7,718,608
7,902,206
7,906,542
7,915,275
7,935,799
8,158,644
8,158,781
8,193,196
8,309,569
8,518,949
8,642,573
8,741,904
8,829,017
8,835,452
8,853,231
8,946,252
8,969,398
|
| Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00777 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,282,966 |
| Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00778 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,431,163 |
| Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00779 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,293,284 |
| Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00780 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,795,741 |
| Praxair Distribution, Inc. v. Mallinckrodt Hospital Products IP Ltd., IPR2016-00781 (PTAB) | Mar. 23, 2016 | N/A | Inomax® (nitric oxide) | 8,846,112 |
| Genzyme Corp. v. Sun Pharma Global FZE, 16-1635 (D.N.J.) | Mar. 24, 2016 | Hon. Claire C. Cecchi | Clolar® (clofarabine for injection) | 5,661,136 |
| AstraZeneca AB v. Macleods Pharms. Ltd., 16-1682 (D.N.J.) | Mar. 24, 2016 | Hon. Mary L. Cooper | Nexium® (esomeprazole magnesium delayed-release capsules) |
6,369,085
7,411,070
8,466,175
|
| Helsinn Healthcare S.A. v. Actavis LLC, 16-1683 (D.N.J.) | Mar. 24, 2016 | Hon. Mary L. Cooper | Aloxi® (palonosetron hydrochloride for injection) |
7,947,724
9,066,980
|
| Gilead Sciences, Inc. v. Mylan Pharms. Inc., 16-0192 (D. Del.) | Mar. 25, 2016 | Hon. Richard G. Andrews | Tybost® (cobicistat tablets) | 8,148,374 |
| Rhodes Pharms. L.P. v. Actavis, Inc., 16-1668 (D.N.J.) | Mar. 25, 2016 | Hon. William H. Walls | Aptensio XR® (methylphenidate hydrochloride extended-release capsules) |
6,419,960
7,083,808
7,247,318
7,438,930
8,580,310
9,066,869
|
| Alcon Research, Ltd. v. Lupin Ltd., 16-0195 (D. Del.) | Mar. 28, 2016 | Hon. Sue L. Robinson | Pazeo® (olopatadine hydrochloride ophthalmic solution) | 8,791,154 |
| Boehringer Ingelheim Pharms. Inc. v. Sun Pharm. Industries Ltd., 16-1727 (D.N.J.) | Mar. 29, 2016 | Hon. Peter G. Sheridan |
Tradjento® (linagliptin tablets)
Jentadueto® (linagliptin / metformin hydrochloride tablets)
|
9,173,859 |
| Gilead Sciences, Inc. v. Mylan Pharms. Inc., 16-0053 (N.D.W.V.) | Mar. 30, 2016 | Hon. Irene M. Keeley | Tybost® (cobicistat tablets) | 8,148,374 |
| Galderma Labs., L.P. v. Amneal Pharms., LLC, 16-0207 (D. Del.) | Mar. 31, 2016 | Hon. Leonard P. Stark | Oracea® (doxycycline capsules) |
7,211,267
7,232,572
8,603,506
9,241,946
7,749,532
8,206,740
8,394,405
8,394,406
8,470,364
8,709,478
|
| Merck Sharp & Dohme Corp. v. Roxane Labs., Inc., 16-1804 (D.N.J.) | Mar. 31, 2016 | Hon. Peter G. Sheridan | Noxafil® (posaconazole oral suspension) |
5,661,151
6,958,337
|
| United Therapeutics Corp. v. Actavis Labs. FL, Inc., 16-1816 (D.N.J.) | Mar. 31, 2016 | Hon. Peter G. Sheridan | Orenitram® (treprostinil extended-release tablets) |
7,417,070
7,544,713
8,252,839
8,349,892
8,410,169
8,497,393
9,050,311
8,747,897
9,278,910
|
